Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$14.00
+1.4%
$11.38
$8.02
$18.55
$6.95B1.675.20 million shs6.43 million shs
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$131.87
$131.87
$66.26
$131.98
$14.05B0.691.58 million shsN/A
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
$109.64
+1.1%
$107.97
$95.49
$148.06
$6.63B0.33833,494 shs592,969 shs
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
$2.16
+1.4%
$2.07
$1.67
$10.03
$550.07M0.252.33 million shs1.01 million shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.00%-0.90%+6.84%+29.83%-23.35%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
0.00%0.00%0.00%+0.32%+94.58%
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
0.00%-2.37%-0.44%-22.62%-3.91%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
0.00%-10.88%+1.43%-19.32%-71.68%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
1.0286 of 5 stars
1.22.00.00.31.31.70.0
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
0.6809 of 5 stars
1.10.00.04.50.01.70.6
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
4.9426 of 5 stars
4.52.00.04.02.73.33.1
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
3.9483 of 5 stars
3.13.00.04.41.50.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.43
Hold$15.178.31% Upside
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
2.17
Hold$109.70-16.81% Downside
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
2.92
Moderate Buy$184.0067.82% Upside
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
2.25
Hold$6.64207.36% Upside

Current Analyst Ratings Breakdown

Latest MRVI, ITCI, ELAN, and JAZZ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$202.00
6/3/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$202.00
5/19/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $16.00
5/13/2025
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $10.00
5/13/2025
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$3.00 ➝ $2.00
5/8/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$13.00 ➝ $15.00
5/7/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$182.00 ➝ $172.00
5/7/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$167.00 ➝ $155.00
5/7/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$176.00 ➝ $147.00
5/7/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$183.00 ➝ $166.00
5/7/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$200.00 ➝ $200.00
(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.43B1.57$2.89 per share4.84$12.63 per share1.11
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$680.50M20.64N/AN/A$6.15 per share21.44
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
$4.06B1.63$22.33 per share4.91$59.36 per share1.85
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
$241.86M2.27$0.05 per share41.71$3.14 per share0.69
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$1.23B$0.7435.0115.732.504.60%6.78%3.03%8/6/2025 (Estimated)
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%N/A
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
$414.83M$7.5015.445.861.0411.60%29.30%9.72%7/30/2025 (Estimated)
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-$119.03M-$1.14N/AN/AN/A-81.13%-6.61%-3.45%8/6/2025 (Estimated)

Latest MRVI, ITCI, ELAN, and JAZZ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-$0.07-$0.08-$0.01-$0.21$44.01 million$46.85 million
5/7/2025Q1 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.31$0.37+$0.06$0.14$1.17 billion$1.19 billion
5/6/2025Q1 2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
$4.65$1.68-$2.97-$1.52$984.16 million$897.84 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/AN/AN/AN/AN/A
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
N/AN/AN/AN/AN/A
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.66
2.55
1.31
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/A
7.66
7.51
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
1.46
4.26
3.74
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
0.89
10.74
9.94

Institutional Ownership

CompanyInstitutional Ownership
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
92.33%
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
89.14%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
50.25%
CompanyEmployeesShares OutstandingFree FloatOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,800496.65 million491.54 millionOptionable
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
560106.52 million103.56 millionOptionable
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
3,20060.51 million57.92 millionOptionable
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
610254.66 million250.94 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$14.00 +0.19 (+1.40%)
Closing price 03:59 PM Eastern
Extended Trading
$13.51 -0.49 (-3.52%)
As of 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Intra-Cellular Therapies stock logo

Intra-Cellular Therapies NASDAQ:ITCI

$131.87 0.00 (0.00%)
As of 04/2/2025

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Jazz Pharmaceuticals stock logo

Jazz Pharmaceuticals NASDAQ:JAZZ

$109.64 +1.14 (+1.05%)
Closing price 04:00 PM Eastern
Extended Trading
$109.69 +0.05 (+0.05%)
As of 05:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Maravai LifeSciences stock logo

Maravai LifeSciences NASDAQ:MRVI

$2.16 +0.03 (+1.41%)
Closing price 04:00 PM Eastern
Extended Trading
$2.16 +0.00 (+0.23%)
As of 06:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.